Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

The conditional marketing authorization for Advanz Pharma’s liver disease treatment Ocaliva has been revoked following a decision by the General Court of the European Union, the company announced Wednesday. The court decided not to extend ...